Not applicableLooking for participantsNCT07169396What this trial is testingIdentifying Genetic Targets in Gynecological TumorsWho this might be right forOvarian Cancer Azienda USL Reggio Emilia - IRCCS 180
Not applicableStudy completedNCT02973750What this trial is testingDeterminants of Age-Related Treatment Effectiveness in Ovarian CancerWho this might be right forOvarian CancerFallopian Tube CancerPeritoneal Cancer+3 more H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)UnknownNCT04261465What this trial is testingNUVOLA TRIAL Open-label Multicentre StudyWho this might be right forHigh Grade Serous Ovarian Cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS 35
Not applicableUnknownNCT05069818What this trial is testingVariance of HRD From Paired Ovarian CancerWho this might be right forOvarian CancerHRDPlatinum-sensitive Ovarian Cancer Xiaoxiang Chen 50
Early research (Phase 1)Looking for participantsNCT05005403What this trial is testingStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanWho this might be right forNon-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMicro Satellite Stable Colorectal Cancer+4 more AbbVie
Not applicableLooking for participantsNCT03419689What this trial is testingStudy Looking at Biomarkers in Ovarian CancerWho this might be right forGynecologic Cancer University Health Network, Toronto 510
Not applicableLooking for participantsNCT06466382What this trial is testingOV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer TherapyWho this might be right forOvarian Neoplasm EpithelialFallopian Tube NeoplasmsOvarian Endometrioid Carcinoma+1 more Swiss GO Trial Group 60
Not applicableStudy completedNCT03622385What this trial is testingExploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian CancerWho this might be right forEpithelial Ovarian Cancer Baylor Research Institute 10
Early research (Phase 1)Ended earlyNCT05229900What this trial is testingSGN-ALPV in Advanced Solid TumorsWho this might be right forOvarian NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung+4 more Seagen Inc. 43
Not applicableStudy completedNCT06787170What this trial is testingPrediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian CancerWho this might be right forHigh-grade Serous Ovarian Cancer (HGSOC) The First People's Hospital of Yunnan 1,129
Large-scale testing (Phase 3)Study completedNCT01968213What this trial is testingPhase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)Who this might be right forOvarian CancerFallopian Tube CancerPeritoneal Cancer pharmaand GmbH 564
Early research (Phase 1)Ended earlyNCT05274451What this trial is testingInvestigate LYL797 in Adults With Solid TumorsWho this might be right forTriple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more Lyell Immunopharma, Inc. 57
Large-scale testing (Phase 3)Ended earlyNCT05329545What this trial is testingUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Who this might be right forHigh Grade Serous Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer Mersana Therapeutics 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927What this trial is testingTesting the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerWho this might be right forFallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)UnknownNCT06161272What this trial is testingFluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiWho this might be right forOvarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more Guangxi Medical University 80
Not applicableLooking for participantsNCT05027828What this trial is testingCtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian CancerWho this might be right forHigh-grade Serous Ovarian CancerCirculating Tumor DNA Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 100
Testing effectiveness (Phase 2)Looking for participantsNCT05329532What this trial is testingModi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerWho this might be right forTriple Negative Breast CancerRenal Cell CancerHigh Grade Ovarian Serous Adenocarcinoma+1 more Scancell Ltd 168
Early research (Phase 1)Ended earlyNCT03585764What this trial is testingMOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forOvarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma University of Pennsylvania 46
Testing effectiveness (Phase 2)UnknownNCT05065021What this trial is testingUsing Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorWho this might be right forOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+2 more University Health Network, Toronto 40
Not applicableLooking for participantsNCT06777082What this trial is testingRole of RPL8 Protein Alterations in High-grade Serous Ovarian CarcinomaWho this might be right forHigh Grade Serous Ovarian Cancer IRCCS Azienda Ospedaliero-Universitaria di Bologna 150